For the committee, some of the reasons it used to reject adding Pompe disease to Australia’s newborn bloodspot screening programs are perversely the same as those it invoked to support the addition of Hurler (MPS I) and Hunter (MPS II) syndromes.
Decision-making at its nadir, exposing the cruelty of incoherence
September 16, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Todd Stephenson confirmed on ACT list for New Zealand election
September 14, 2026 - - Latest News -
Scandal-hit KPMG still holds $37 million in health department work
September 14, 2026 - - Latest News -
Canberra details tax changes with limited concessions for some innovators
September 14, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 11 September
September 11, 2026 - - Podcast -
Rare genetic motor neurone disease treatment finally reaches Australian patients
September 11, 2026 - - Latest News -
NSW pharmacists to deliver all childhood vaccines and treat more conditions under reforms
September 11, 2026 - - Latest News -
AI Health Summit 2026
September 10, 2026 - - Summit
